PBYI - Bathi operasional EBITDA pumabiotechnology.com

Tandha merek Puma Biotechnology, Inc. (PBYI)

Debt obligations and the risk of generic competition constrain the investment potential of Puma Biotechnology (PBYI). However, the exclusive targeted therapy Nerlynx effectively captures the HER2-positive cancer treatment niche, while stable sales ensure a steady inflow of funds. The absolute EBITDA trend on GURU.Markets confirms the resilience of the cash flow, while the 40.86 metric indicates the current scale of the company's operating profit.

Puma Biotechnology (PBYI) - Bathi operasional EBITDA saka 23.11.2025 nganti 10.11.2026

Ringkesan rincian data analitis Puma Biotechnology, Inc. (PBYI)

- kuotasi saiki lan rata-rata prakiraan nilai:
Kutipan saham Puma Bio|PBYI - Prakiraan konsensus analis
- statistik kapitalisasi pasar:
Kapitalisasi pasar Puma Biotechnology|PBYI - Nilai Total Perusahaan
- indikator nilai buku ekuitas:
Ekuitas saben Saham Puma Biotechnology|PBYI - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih pumabiotechnology.com|PBYI - Total Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Utang marang Modal Puma Biotechnology|PBYI - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Puma Bio|PBYI - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku Puma Biotechnology|PBYI - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Puma Biotechnology|Indikator likuiditas cepet pumabiotechnology.com
- indikator bathi lan kelipatan valuasi:
PBYI - Bathi resik|Proyeksi bathi mangsa ngarep Puma Biotechnology|PBYI - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Puma Bio|PBYI - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Puma Biotechnology|PBYI - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Puma Biotechnology|PBYI - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan pumabiotechnology.com|PBYI - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Puma Biotechnology
Analisis kabeh metrik perusahaan:Puma Biotechnology, PBYI
Produk asil prodhuksi Puma Biotechnology Inc

Puma Biotechnology's stable patient base and the expansion of therapeutic indications are reflected in the EBITDA_Co level on this chart, demonstrating the actual scale of operating cash flow. This metric measures earnings before depreciation, interest, and taxes, allowing investors to assess the efficiency of the core business regardless of debt load, which is critical for analyzing the company's resilience in a mature segment.

Analisis pesaing Puma Biotechnology

OLMA - Bathi operasional sadurunge ngurangi amortisasi|Greenwich LifeSciences - Bathi operasional EBITDA|ZNTL - Bathi operasional EBITDA|MacroGenics (MGNX) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi operasional sadurunge amortisasi PSTV|PCSA (Processa Pharmaceuticals Inc.) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi Eagle Pharma (EGRX)